Spots Global Cancer Trial Database for ro6870810
Every month we try and update this database with for ro6870810 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | NCT03292172 | Advanced Ovaria... Triple Negative... | Atezolizumab RO6870810 | 18 Years - | Hoffmann-La Roche | |
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | NCT03292172 | Advanced Ovaria... Triple Negative... | Atezolizumab RO6870810 | 18 Years - | Hoffmann-La Roche | |
A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome | NCT02308761 | Acute Myeloid L... Myelodysplastic... | RO6870810 | 18 Years - | Hoffmann-La Roche | |
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 | NCT03255096 | Diffuse Large B... High-Grade B-ce... | RO6870810 Venetoclax Rituximab | 18 Years - | Hoffmann-La Roche | |
A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome | NCT02308761 | Acute Myeloid L... Myelodysplastic... | RO6870810 | 18 Years - | Hoffmann-La Roche | |
Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma | NCT03068351 | Multiple Myelom... | RO6870810 daratumumab | 18 Years - | Hoffmann-La Roche | |
A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies | NCT01987362 | Solid Tumors, A... | RO6870810 | 18 Years - | Hoffmann-La Roche |